The pharmacological mechanism of Abelmoschus manihot in the treatment of chronic kidney disease
Cuiting Wei,
Chao Wang,
Run Li,
Yunfeng Bai,
Xue Wang,
Qingyun Fang,
Xiangmei Chen,
Ping Li
Affiliations
Cuiting Wei
Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China; Department of Nephrology, First Medical Center of Chinese People's, Liberation Army (PLA) General Hospital, Nephrology Institute of the Chinese, People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
Chao Wang
Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China; Department of Nephrology, First Medical Center of Chinese People's, Liberation Army (PLA) General Hospital, Nephrology Institute of the Chinese, People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
Run Li
Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China; Department of Nephrology, First Medical Center of Chinese People's, Liberation Army (PLA) General Hospital, Nephrology Institute of the Chinese, People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
Yunfeng Bai
Department of Nephrology, First Medical Center of Chinese People's, Liberation Army (PLA) General Hospital, Nephrology Institute of the Chinese, People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
Xue Wang
Department of Nephrology, First Medical Center of Chinese People's, Liberation Army (PLA) General Hospital, Nephrology Institute of the Chinese, People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
Qingyun Fang
Department of Nephrology, First Medical Center of Chinese People's, Liberation Army (PLA) General Hospital, Nephrology Institute of the Chinese, People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
Xiangmei Chen
Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China; Department of Nephrology, First Medical Center of Chinese People's, Liberation Army (PLA) General Hospital, Nephrology Institute of the Chinese, People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China; Corresponding author. Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.
Ping Li
Department of Nephrology, First Medical Center of Chinese People's, Liberation Army (PLA) General Hospital, Nephrology Institute of the Chinese, People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China; Corresponding author.
Abelmoschus manihot (A.manihot) is a herbaceous flowering medicinal plant and flavonoids are its main pharmacological active ingredients. A.manihot is listed in the 2020 edition of the Chinese Pharmacopoeia for the treatment of chronic kidney disease (CKD). A.manihot significantly reduces proteinuria in CKD, and the effectiveness and safety of A.manihot in the treatment including primary glomerulonephropathy and diabetic kidney disease (DKD) have been proved by several randomized controlled trials (RCT). Emerging pharmacological studies have explored the potential active small molecules and the underlying mechanisms in A.manihot. The active constituents of A.manihot are mainly seven flavonoids, including hibifolin, hyperoside, isoquercetin, rutin, quercetin, myricetin, and quercetin-3-O-robinobioside. The mechanisms of action mainly include alleviating renal fibrosis, reducing the inflammatory response and decreasing the apoptosis of podocytes. In this review, we summarize the updated information of active components and molecular mechanisms of A.manihot on chronic kidney disease.
